foxo4 dri senolytic human trial 2024 study FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells FOXO4-DRI: The Senolytic Peptide That – Peptide Inhibitors Targeting FOXO4-p53 Interactions

Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging Cellular Senescence as a Targetable Risk Factor for Cardiovascular Diseases: Therapeutic Implications: JACC Family Series JACC: Basic to Translational Science The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications

SKU: 54701818631 · From www.marsberger-treibhaus.de